The COVID-19 Pandemic
Autor: | Klaus Rose |
---|---|
EAN: | 9780323993876 |
eBook Format: | ePUB |
Sprache: | Englisch |
Produktart: | eBook |
Veröffentlichungsdatum: | 14.03.2022 |
Untertitel: | A Global High-Tech Challenge at the Interface of Science, Politics, and Illusions |
Kategorie: | |
Schlagworte: | COVID-19; Pandemic; Public Health; Healthcare Structures; Vaccine Skepticism |
131,00 €*
Versandkostenfrei
Die Verfügbarkeit wird nach ihrer Bestellung bei uns geprüft.
Bücher sind in der Regel innerhalb von 1-2 Werktagen abholbereit.
The COVID-19 Pandemic: A Global High-Tech Challenge at the Interface of Science, Politics, and Illusions discusses COVID-19 from a historical basis. Many of today's key decisions are based on flawed assumptions and blind spots, including the belief that healthcare institutions, researchers and authorities are driven by patients' interests, while industry is greedy. Examples include the US Operation Warp Speed to expedite the development of tools against the pandemic, the EU's inability to establish a working relationship with vaccine developers, and the success stories of countries such as Israel and Taiwan.
This book offers scientists and interested persons orientation and helps to decipher statements from governments and authorities. It will help professionals involved in the approval, planning, implementation and evaluation of COVID-19 studies to distinguish meaningful from pointless.
- Analyzes key features of the pandemic on the historical background of mankind's development from hunters and gatherers to modern civilization
- Opens eyes to the self-interests of institutions and professional associations and resulting conflicts of interest
- Helps healthcare professionals address critical questions
Dr. Rose MD, MS is a medical doctor by training and profession. In the mid-90's, after clinical training, he joined the pharmaceutical industry. While at Novartis, in Switzerland, in 1997 he came across clinical studies in children and was intrigued. His eldest daughter suffers from Sturge-Weber syndrome, which is serious and very rare. Dr. Rose became passionate about 'pediatric drug development” and what the European Medicines Agency (EMA) called 'Better Medicines for Children”. He was then global head of pediatrics at Novartis from 2001-2005 and moved to the same position at Genentech/Roche 2005-2009 in Basel. After one more year at a regulatory company he became an independent consultant in 2011. He has advised companies on European Medicines Agency (EMA) 'pediatric investigation plans” (PIPs) and Food and Drug Administration (FDA) pediatric requests/demands.